ES2095802A1 - Composicion farmaceutica estabilizada y solvente de estabilizacion. - Google Patents

Composicion farmaceutica estabilizada y solvente de estabilizacion.

Info

Publication number
ES2095802A1
ES2095802A1 ES09402047A ES9402047A ES2095802A1 ES 2095802 A1 ES2095802 A1 ES 2095802A1 ES 09402047 A ES09402047 A ES 09402047A ES 9402047 A ES9402047 A ES 9402047A ES 2095802 A1 ES2095802 A1 ES 2095802A1
Authority
ES
Spain
Prior art keywords
solvent
pharmaceutical composition
carboxylate anion
stabilized pharmaceutical
anion content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES09402047A
Other languages
English (en)
Inventor
Shreerham Nara Agharkar
Uday S Gogate
Thomas Cavanak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2095802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ES2095802A1 publication Critical patent/ES2095802A1/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSICION FARMACEUTICA ESTABILIZADA Y SOLVENTE DE ESTABILIZACION. COMPOSICION FARMACEUTICA ESTABILIZADA QUE CONTIENE PACLITAXEL, TENIPOSIDO, CAMPTOTECINA U OTROS AGENTES ANTINEOPLASICOS SUSCEPTIBLES A LA DEGRADACION DURANTE EL ALMACENAMIENTO, QUE SE PRODUCE UTILIZANDO UN SISTEMA DE SOLVENTES QUE CONTIENE UN BAJO CONTENIDO DE ANION CARBOXILATO. EL SISTEMA DE SOLVENTES ES UNA MEZCLA DE ETANOL Y ACEITE DE RICINO POLIOXIETILADO. EL ACEITE DE RICINO POLIOXIETILADO ES TRATADO CON UN ACIDO O PUESTO EN CONTACTO CON ALUMINA PARA REDUCIR EL CONTENIDO DE ANION CARBOXILATO DEL SOLVENTE. EL BAJO CONTENIDO DE ANION CARBOXILATO DEL SOLVENTE PROPORCIONA UNA VIDA DE ALMACENAMIENTO PROLONGADA Y DISMINUYE LA CANTIDAD DE SUBPRODUCTOS DE DEGRADACION.
ES09402047A 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion. Withdrawn ES2095802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (1)

Publication Number Publication Date
ES2095802A1 true ES2095802A1 (es) 1997-02-16

Family

ID=22433231

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94115180T Expired - Lifetime ES2098842T3 (es) 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante.
ES09402047A Withdrawn ES2095802A1 (es) 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94115180T Expired - Lifetime ES2098842T3 (es) 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante.

Country Status (28)

Country Link
US (1) US5504102A (es)
EP (1) EP0645145B1 (es)
JP (1) JP3447386B2 (es)
KR (1) KR100515631B1 (es)
CN (1) CN1140297C (es)
AT (1) ATE149843T1 (es)
AU (1) AU686651B2 (es)
BE (1) BE1007987A5 (es)
BR (1) BR1100361A (es)
CA (1) CA2132936C (es)
CY (1) CY2035A (es)
CZ (2) CZ287358B6 (es)
DE (1) DE69402022T2 (es)
DK (1) DK0645145T3 (es)
ES (2) ES2098842T3 (es)
FI (1) FI115825B (es)
GR (1) GR3023583T3 (es)
HK (1) HK96797A (es)
HU (1) HU217962B (es)
IL (1) IL111065A (es)
IT (1) IT1279383B1 (es)
NO (1) NO308447B1 (es)
NZ (1) NZ264526A (es)
PL (1) PL176826B1 (es)
RU (1) RU2107500C1 (es)
SG (1) SG50479A1 (es)
TW (1) TW406020B (es)
ZA (1) ZA947482B (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
CA2628857C (en) * 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
DE19983660T1 (de) * 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
AU2001247739A1 (en) * 2000-03-24 2001-10-08 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
WO2001076559A1 (en) 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
US7550157B2 (en) 2000-05-12 2009-06-23 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
EP1313466A4 (en) * 2000-08-02 2005-11-23 Atossa Healthcare Inc BIMODAL EMULSIONS OF TAXANES AND BUTYRATE POLYALCOHOL ESTERS
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
SK7092003A3 (en) 2000-11-09 2004-06-08 Neopharm Inc SN-38 lipid complexes and methods of use
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
DE60136648D1 (de) 2000-12-05 2009-01-02 Los Angeles Childrens Hospital Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
JP2005500988A (ja) 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
CN100500221C (zh) * 2002-07-15 2009-06-17 爱尔康公司 用于眼科药物递送的生物可侵蚀膜剂
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
AU2003291458A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
WO2004100994A2 (de) * 2003-05-19 2004-11-25 Ebewe Pharma Ges.M.B.H. Nfg.Kg Werfahren zur herstellung einer stabilen injizierbaren formulierung von schwer löslichen antineoplastischen wirkstoffen
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
EP1648988A1 (en) * 2003-07-24 2006-04-26 Dabur Research Foundation Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1694660B1 (en) * 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
MXPA06006710A (es) * 2003-12-17 2006-08-31 Bionumerik Pharmaceuticals Inc Formulaciones farmaceuticas de camptotecinas y proceso para su elaboracion.
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
WO2008105852A2 (en) * 2006-10-26 2008-09-04 Creighton University Mucoadhesive nanoparticles for cancer treatment
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
TWI441639B (zh) * 2008-02-20 2014-06-21 Actelion Pharmaceuticals Ltd 用於治療卵巢癌之包含紫杉醇之組合
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
AU2009350151B2 (en) 2009-07-20 2015-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
AU2011327824B2 (en) * 2010-11-08 2016-06-02 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
TWI599373B (zh) * 2012-08-15 2017-09-21 永信藥品工業股份有限公司 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之穩定醫藥調配物
WO2014123935A1 (en) * 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2221157A (en) * 1988-07-21 1990-01-31 Biogal Gyogyszergyar Intravenous pharmaceutical composition comprising cyclosporin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2221157A (en) * 1988-07-21 1990-01-31 Biogal Gyogyszergyar Intravenous pharmaceutical composition comprising cyclosporin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. n‘ 14, N‘ 475 (C-770) [4418], 1990 & JP 2196789 A (SANKYO CO. LTD.) *

Also Published As

Publication number Publication date
BR1100361A (pt) 2000-07-18
AU7427394A (en) 1995-04-13
NO943583L (no) 1995-03-30
KR950007872A (ko) 1995-04-15
CZ234994A3 (en) 1995-04-12
IL111065A0 (en) 1994-12-29
CA2132936C (en) 1999-06-29
ZA947482B (en) 1995-05-15
ATE149843T1 (de) 1997-03-15
FI115825B (fi) 2005-07-29
DK0645145T3 (da) 1997-04-07
FI944448A (fi) 1995-03-30
CN1140297C (zh) 2004-03-03
CN1107367A (zh) 1995-08-30
DE69402022D1 (de) 1997-04-17
IL111065A (en) 2003-03-12
US5504102A (en) 1996-04-02
HUT68687A (en) 1995-07-28
DE69402022T2 (de) 1997-07-17
ITRM940621A0 (it) 1994-09-28
NO943583D0 (no) 1994-09-27
NO308447B1 (no) 2000-09-18
IT1279383B1 (it) 1997-12-10
TW406020B (en) 2000-09-21
CZ287485B6 (cs) 2000-12-13
JP3447386B2 (ja) 2003-09-16
CY2035A (en) 1998-02-20
AU686651B2 (en) 1998-02-12
NZ264526A (en) 1996-10-28
BE1007987A5 (fr) 1995-12-05
HK96797A (en) 1997-08-08
RU2107500C1 (ru) 1998-03-27
PL305240A1 (en) 1995-04-03
RU94037231A (ru) 1996-09-27
EP0645145A2 (en) 1995-03-29
EP0645145B1 (en) 1997-03-12
SG50479A1 (en) 1998-07-20
JPH07179362A (ja) 1995-07-18
KR100515631B1 (ko) 2005-12-08
HU9402776D0 (en) 1994-12-28
GR3023583T3 (en) 1997-08-29
CA2132936A1 (en) 1995-03-30
CZ287358B6 (en) 2000-11-15
PL176826B1 (pl) 1999-07-30
HU217962B (hu) 2000-05-28
ES2098842T3 (es) 1997-05-01
ITRM940621A1 (it) 1996-03-28
FI944448A0 (fi) 1994-09-26
EP0645145A3 (en) 1995-05-24

Similar Documents

Publication Publication Date Title
ES2095802A1 (es) Composicion farmaceutica estabilizada y solvente de estabilizacion.
IL90052A (en) :-substituted 4-(quinolin- 2-yl-methoxy) phenylacetic acids and esters, their preparation and pharmaceutical compositions containing them
UA29406C2 (uk) Складні ефіри трициклічних аміноспиртів
AU4081089A (en) Morphine-containing composition
IE861813L (en) New Polysaccharide Esters and their Salts
AU7993694A (en) Novel pyrazine carboxamide derivatives, their production and their use in medicaments
KR900002802A (ko) 면역억제제로서의 트랜스글루타미나제의 용도
JPS6416724A (en) Stable and injectable vinca dimer salt solution
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
IE881410L (en) Anticoccidial composition
US5037655A (en) Method of stabilizing tretinoin
JPS5218811A (en) Preparation of aqueous solution of fat- soluble substances
KR950702561A (ko) 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
EP0340933A3 (en) Heparin-containing formulations
IE780530L (en) Anti-histamine salts and compositions
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
TH13516A (th) องค์ประกอบเภสัชกรรม
TW252042B (en) Injectable pharmaceutical composition containing piroxicam potassium
CA2153570A1 (en) Pharmaceutical composition for treating nicotine dependence

Legal Events

Date Code Title Description
FB1A Application suspended

Effective date: 19960617

EC2A Search report published

Date of ref document: 19970216

Kind code of ref document: A1

Effective date: 19970216

FA2A Application withdrawn

Effective date: 19970415